JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 18:17:00 EET | Press release
The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level
Workato Named a Leader in the 2023 Gartner® Magic Quadrant™ for iPaaS3.2.2023 18:15:00 EET | Press release
Workato, the leading enterprise automation and integration platform, announced today that it has again been recognised as a Leader in the 2023 Gartner® Magic Quadrant™ for Integration Platform as a Service. Workato has been named a Leader all five years it has participated in the Gartner® Magic Quadrant™ for iPaaS. The report evaluated 16 total software vendors and placed Workato in the Leaders quadrant for its ability to execute, and completeness of vision. For us, Workato’s position within the Leaders quadrant signals one of the best positionings of a modern iPaaS to date. The Workato platform enables enterprises to automate their business processes across the entire organization by integrating their applications, data, and experiences. Designed with best-in-class security and governance, scalability, performance, and availability, Workato’s low-code, no-code platform makes it easy for IT and business teams to integrate their applications and automate their processes, drawing from th
Suzano Eucafluff to Attend INDEX and CIDPEX in 20233.2.2023 16:58:00 EET | Press release
Suzano, the world’s largest hardwood pulp producer, will showcase its highly sustainable and innovative eucalyptus-based fluff pulp, Eucafluff®, at this year’s INDEX and CIDEPX conferences in Geneva and Nanjing, for the second consecutive year. These two conferences gather the pulp industry’s leading participants in nonwoven materials comprising decision-makers, managers, and technical personnel. Suzano will be presenting significant advancements in Eucafluff’s product application and performance. INDEX is one of the world’s largest nonwovens exhibitions exploring the industry’s latest trends and innovations. The event takes place on 18-21 April 2023 in Geneva, Switzerland. CIDPEX – The China International Disposable Paper Expo - is another important event for Suzano which stages the latest advancements across the tissue paper and disposable hygiene products sector. The event takes place on 12-16 May 2023 in Nanjing, China. Eucafluff® is made from sustainably managed eucalyptus farms i
Uptime Institute Completes Acquisition of CNet Training, the International Award-Winning Technical Education Company3.2.2023 16:01:00 EET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, a Dominus Capital, L.P. portfolio company, announced today that it has completed its acquisition of Academia Group Limited and all of its global subsidiaries including CNet Training, Ltd. CNet Training, located in Bury Saint Edmunds, Suffolk, England, is an International award-winning technical education company. CNet Training has been designing and delivering professional network and data center infrastructure training programs since 1996 and has trained over 83,000 data center professionals across 45 countries. “The data center industry is one of the fastest growing markets in the world. The continued, extraordinary industry expansion requires a growing and diverse workforce, however concerns over the industry’s ability to attract, educate, and retain skilled technical staff persist. This acquisition will help our respective customers thrive in a rapidly changing ecosystem, by giving them access to a range of world class
Dexlevo’s GOURI Symposium and Brand Event at IMCAS 20233.2.2023 11:15:00 EET | Press release
Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris. IMCAS (International Master Course on Aging Science), held from Jan 26th to Jan 28th in Paris, France, is one of the world's three major aesthetics anti-aging societies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005935/en/ GOURI Booth at IMCAS Paris 2023 (Photo: Business Wire) Over 200 doctors and companies who visited Dexlevo's booth showed great interest in GOURI – a unique injectable that provides a fundamental solution to anti-aging. GOURI symposium titled “Universal Anti-Aging Treatment” was conducted by an Australian dermatologist Dr. Paul Han, who apart from giving a lecture also demonstrated a new GOURI treatment protocol which lately has gained increasing popularity among doctors who use GOURI. Dr. Paul commented, “While keeping
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom